Board summary
Key figures
17,904
Registered population
50.1% aged 18–64
35.8%
Aged 65+
ICB 19.9% · England 17.9%
2.2%
Ethnic minority (non-White)
0.8% Asian · England 9.6%
15.9%
In IMD quintile 1
ICB 17.1% · England 21.0%
~2,536
Core20 residents (est.)
Resident basis; registered basis ~2,567 · see page 3
4,320
Hypertension register
+5.25% in 3 yrs · England +5.60%
195
SMI register
13.8% of Folkestone and Hythe's
775
COPD register
Reviews -9.38% in 3 yrs
Forecast to 2030
4,927
Hypertension patients, 2030
+607 on today
71.1%
QRISK ≥20% on statins, 2030
+4.20pp over 3 yrs
8.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail England.
Only 50.7% of asthma patients had an annual review (England 65.7%, ICB 60.4%), leaving about 620 of 1,252 patients unreviewed.
SMI blood pressure checks fell and lag.
SMI blood pressure checks stand at 70.1% (England 83.4%, ICB 79.7%), falling 2.7 pp over 2023 to 2025 while England rose +4.4 pp.
Under-80 hypertension BP control improved faster.
Under-80 hypertension blood pressure control rose +17.5% over 2023 to 2025 (England +3.2%), and overall treatment to target grew +10.9% (England +3.6%).
Population, age and ethnicity
At 35.8%, registered patients aged 65+ substantially exceed England's 17.9%
The Marsh PCN cares for 17,904 registered patients across three practices. Of these, 35.8% (6,403 patients) are aged 65+, markedly higher than Folkestone and Hythe (25.7%), NHS Kent and Medway ICB (19.9%), and England (17.9%). Conversely, 14.1% (2,532 patients) are aged 0-17, below the borough (17.4%), ICB (20.7%), and England (19.6%). Census data indicates 97.8% of local residents are White, compared with 92.6% in Folkestone and Hythe, 88.6% in the ICB, and 81.1% nationally (2.2% non-White ethnic minority share). Ethnicity reflects Census usual residents, not registered patients.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Folkestone and Hythe local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Folkestone & Hythe LA) | 1,699 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.2% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.6% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Folkestone & Hythe LA) | 856 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Folkestone & Hythe LA) | 16.0 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
PCN Core20 share is 15.9% but spans 21.3 percentage points across practices
PCN Core20 share is 15.9%, below Folkestone and Hythe (21.7%), NHS Kent and Medway ICB (17.1%) and England (21.0%), with an average IMD decile of 3.8 (England 5.5). Deprivation is polarised across practices: a 21.3 pp spread divides Oak Hall (21.3%, 1,276 estimated patients) and Church Lane Health Centre (20.1%, 1,291 estimated patients) from Martello Health Centre (0.0%). The weighted practice Core20 share is 14.3%, differing by 1.56 percentage points from the PCN figure. This concentration points to focusing deprivation-linked outreach in the two affected practices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
195
SMI register
1.10% recorded prevalence
209
Learning disability register
1.18% recorded prevalence
21
Care homes, 320 beds
In the PCN catchment
10.2%
Provide unpaid care
Folkestone and Hythe, Census 2021
The PCN records 209 learning disability patients (1.2% prevalence; Folkestone and Hythe 0.9%, ICB 0.6%, England 0.6%) and 195 with severe mental illness (1.1%; England 1.0%). Catchment care homes total 21 (320 beds), though bed capacity does not establish registered patient residence. Higher recorded learning disability prevalence may indicate greater need for annual health checks across member practices.
Severe mental illness: physical health checks
SMI physical health checks trail benchmarks: 70.1% had a blood pressure check (England 83.4%), falling 2.7 pp over 2023 to 2025 (England +4.4 pp), and 70.1% had a BMI record (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,320
Hypertension register
+5.25%
Register growth, 3 yrs
Folkestone and Hythe +5.18% · England +5.60%
+9.80pp
BP control, under 80
≤140/90 · +6.08pp aged 80+
+607
More patients by 2030
Forecast 4,927 (27.08%)
Hypertension case-finding and control
Recorded hypertension prevalence is 24.4% across 4,320 patients, above England (15.2%), Folkestone and Hythe (18.6%) and the ICB (16.2%). While blood pressure control for patients under 80 rose +17.5% over 2023 to 2025 (England +3.2%), current control is 65.8% (England 67.8%). Control for patients aged 80 and over is 76.5% (England 81.2%), and is 69.5% at Martello Health Centre. Overall treatment to target is 66.6% (England 70.3%). Lower control rates than England across older hypertensive cohorts suggest an opportunity to prioritise systematic blood pressure review and treatment optimisation.
Lipids and statins
Lipid-lowering therapy reaches 61.7% of patients with QRISK ≥ 20% (England 63.6%) and 65.8% of CKD patients (England 70.3%). Statin treatment for diabetic patients without prior cardiovascular disease is 69.6% (England 73.2%). Fewer at-risk patients receive lipid coverage than England rates imply, highlighting an opportunity to prioritise targeted statin reviews.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 37,646 | £2.70 | £1.90 | £1.86 | £101,644 |
| Cardiovascular (all), 2025 | 54,290 | £4.02 | £3.57 | £3.33 | £218,246 |
In 2026, the PCN prescribed 37,646 lipid-regulating items at £2.70 per item, exceeding England (£1.86), Folkestone and Hythe (£2.17) and the ICB (£1.90). This represents £31,623 more than at England's unit cost across 37,646 items. Prescribing unit costs exceeding ICB and national benchmarks indicate an opportunity to prioritise lipid-modifying formulary reviews.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+8.84%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.21%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.4% (England 6.6%), yet annual reviews reach 50.7% (England 65.7%), leaving about 620 of 1,252 patients unreviewed. Prescribing for ages 5-19 reaches 2,934 items per 1,000 (England 1,488 rate), while second-hand smoke status recording is 61.8% (England 78.8%). Alongside this, COPD prevalence is 4.4% (England 1.9%) across 775 patients, but reviews fell 9.4% over 2023 to 2025 (England +2.8%) to 69.8% (England 76.4%).
Cancer register and children's immunisation
Cancer register prevalence is 6.9% across 1,219 patients, above England (3.8%) and the ICB (4.4%). In Q1 2025/26, 6-in-1 coverage at 12 months reached 100.0% (England 91.0%). At age 5, MMR dose 1 coverage is 96.4% while dose 2 is 85.7% (England 82.8%, a 10.7 pp dose difference), and 4-in-1 booster coverage is 85.7% (England 80.9%), both below the 95.0% target by 9.3 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
Across NHS Kent and Medway ICB in 2022, 55.6% of cancers with a known stage (4,661 of 8,384 cases) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.4 pp below the 75.0% national ambition. Reaching 75.0% would require about 1,630 extra early-stage diagnoses annually across the ICB, where staging data was recorded for 63.6% of all registered cancers (England 67.0%). Within The Marsh PCN, recorded cancer prevalence is 6.9% (1,219 patients), while cervical screening coverage is 70.3% (England 66.8%) and breast screening is 70.5% (England 69.9%). Sustaining primary care screening uptake and proactive safety-netting remains essential to support earlier-stage diagnosis across the system.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, East Kent Hospitals University NHS Foundation Trust achieved 96.7% on the 31-day cancer standard (standard 96.0%, ICB 95.8%, England 92.5%), but lagged standards for 62-day referral to treatment at 70.0% (standard 85.0%, ICB 75.9%, England 71.2%) and 28-day faster diagnosis at 71.3% (standard 75.0%, ICB 76.8%, England 79.3%). For diagnostics, 48.4% of patients waited 6+ weeks at East Kent Hospitals (England 23.1%; Maidstone and Tunbridge Wells NHS Trust 6.4%), including non-obstetric ultrasound (63.0%) and MRI (47.6%). Prolonged secondary care diagnostic waits may extend time to treatment for patients referred on urgent cancer pathways.
| Pathways within standard (%) | East Kent | East Sussex Healthcare | Maidstone and Tunbridge Wells | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.28 | 84.20 | 81.78 | 76.78 | 79.32 |
| 31-day treatment (96%) | 96.67 | 98.19 | 98.35 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 70.01 | 67.04 | 87.43 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Kent | East Sussex Healthcare | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 47.58 | 6.48 | 0.92 | 21.40 |
| CT | 37.45 | 0.48 | 0.51 | 9.92 |
| Echocardiography | 14.17 | 21.94 | 2.57 | 28.48 |
| Colonoscopy | 9.58 | 0.74 | 19.80 | 30.83 |
| Gastroscopy | 22.16 | 0.31 | 24.03 | 29.02 |
| All 15 DM01 tests | 48.38 | 5.27 | 6.42 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In Jun 2026, 265,905 provisional community care activities were recorded for Kent residents and 297,595 across NHS Kent and Medway Integrated Care Board. Contacts with adults aged 65+ comprised 65.8% of borough residents' community contacts (138,250 of 210,170). Older residents rely heavily on community services alongside PCN long-term condition management.
Practice variation and patient experience
Phone access spans 21.0 pp and vaccination achievement spans 56.2 pp across practices
In 2025/26, clinical QOF achievement was high across all three practices: 97.0% at Church Lane Health Centre, 98.1% at Martello Health Centre, and 99.2% at Oak Hall (England 97.1%). However, vaccination and immunisation achievement spanned 56.2 pp, ranging from 87.0% at Church Lane Health Centre to 53.0% at Martello Health Centre and 30.8% at Oak Hall.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Oak Hall | 125 | 21.3 | 66.9% | 75.3% | 81.8% |
| Martello | 110 | 0.0 | 58.7% | 79.0% | 73.8% |
| Church Lane | 119 | 20.1 | 45.8% | 61.6% | 55.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Chronic disease reviews and mental health checks lag England despite blood pressure gains
Over 2023 to 2025, heart failure annual reviews fell 8.1% (England +8.7%) to 73.6% (England 78.5%), and COPD reviews fell 9.4% (England +2.8%). Across 195 patients on the severe mental illness register, annual blood pressure checks fell 2.7 pp to 70.1% (England +4.4 pp to 83.4%) and alcohol recording fell 4.2 pp to 71.3% (England +5.4 pp to 81.8%). Conversely, blood pressure control under age 80 rose 17.5% (England +3.2%) and hypertension treated to target rose 10.9% (England +3.6%), reflecting delivery gains alongside lagging annual reviews.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Alcohol record (psychosis)
BP check (SMI)
Diabetes HbA1c control
BP control, under 80
Hypertension treated to target
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Folkestone and Hythe | Asset | PCN | Folkestone and Hythe |
|---|---|---|---|---|---|
| Care homes (catchment) | 21 (320 beds) | n/a | Schools (catchment) | 15 | n/a |
| Children's centres | 3 | 8 | Places of worship | 21 | 78 |
| Libraries | 2 | 8 | Food banks (VCS) | n/a | 1 |
| Day centres (VCS) | n/a | 2 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 2 | 21 |
| Primary academies | 4 | 15 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured respiratory and heart failure recall
Asthma reviews reach 50.7% of 1,252 patients (England 65.7%, leaving about 620 unreviewed); COPD fell 9.4% to 69.8% of 775 (England 76.4%, +2.8%); heart failure fell 8.1% to 73.6% of 330 (England 78.5%, +8.7%). For discussion: introduce a single recall template and combined review clinics, starting in the Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Combined SMI physical health check outreach
Across 195 SMI patients, annual blood pressure checks are 70.1% (England 83.4%, ICB 79.7%), falling 2.7 pp over 2023 to 2025 (England +4.4 pp); BMI recording is 70.1% (England 82.1%) and alcohol recording is 71.3% (England 81.8%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Hypertension target and lipid formulary review
Across 4,320 hypertensive patients, treatment to target is 66.6% (England 70.3%) and 80+ control is 76.5% (England 81.2%). QRISK >= 20% lipid therapy is 61.7% (England 63.6%), while 37,646 lipid-modifying items cost £2.70 per item (£31,623 more than at England's £1.86 unit cost). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult proactive care (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Age five booster catch up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Screening recall and safety netting (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Primary care phone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured respiratory and heart failure recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · Combined SMI physical health check outreach (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Option 3 · Hypertension target and lipid formulary review (p12) | Hypertension register · Hypertension patients treated to target · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
